Summary
Substance P and neurokinin-1 (NK-1) receptor antagonists respectively induce cell proliferation and cell inhibition in human cancer cell lines. In acute lymphoblastic leukemia (ALL), substance P is expressed in human blast cells. However, the possible presence of NK-1 receptors in human ALL and the issue of whether the antitumor action of NK-1 receptor antagonists is exerted or not on human ALL (T-ALL BE-13 and B-ALL SD-1 cell lines) remain unknown. An immunoblot analysis was performed and an in vitro study of the cytotoxicity of three NK-1 receptor antagonists (L-733,060, L-732,138, aprepitant) was carried out on both cell lines. NK-1 receptors were found in those cell lines, and both expressed mRNA for this receptor. Using a knockdown method, we demonstrate that NK-1 receptors are involved in the viability of tumor cells. TAC1R cDNA was detected in the ALL cell lines by real-time quantitative RT-PCR. We also observed that the three NK-1 receptor antagonists elicited the inhibition of ALL cell growth; that the specific antitumor action of the NK-1 receptor antagonists occurs through the NK-1 receptor, and that ALL cell death is due to apoptosis. These findings suggest that NK-1 receptor antagonists could be considered as new antitumor drugs for the treatment of human ALL.
Similar content being viewed by others
References
Ries LA, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (1999) SEER cancer statistics review, 1973–1996. National Cancer Institute, Bethesda
Pui CH, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. N Engl J Med 350:1535–1548
Muñoz M, Rosso M, Coveñas R (2010) A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 17:504–513
Ziche M, Morbidelli L, Pacini M, Gepetti P, Alessandri G, Maggi CA (1990) Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvas Res 40:264–278
Luo W, Sharif TR, Sharif M (1996) Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signalling pathway. Cancer Res 56:4983–4991
Muñoz M, Rosso M, Pérez A, Coveñas R, Zamarriego C, Piruat JI (2005) The NK1 receptor is involved in the antitumoural action of L-733, 060 and the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39:427–432
Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Soult JA, Montero I (2005) Antitumoral action of the neurokinin-1-receptor antagonist L-733, 060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 46:2567–2570
Muñoz M, Rosso M, Coveñas R (2006) The NK-1 receptor is involved in the antitumoural action of L-733, 060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discovery 3:323–329
Muñoz M, Rosso M, Soult JA, Coveñas R (2006) Antitumoural action of neurokinin-1 receptor antagonists on human brain cancer cell lines. In: Yang AV (ed) Brain cancer: therapy and surgical intervention. Nova Science, New York, pp 45–75
Muñoz M, Rosso M, Aguilar FJ, González-Moles MA, Redondo M, Esteban F (2008) NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26:111–118
Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M (2008) The NK-1 receptor is involved in the antitumor action of L-733, 060 and in the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol 29:245–254
Muñoz M, Rosso M, González-Ortega A, Coveñas R (2010) The NK-1 receptor antagonist L-732, 138 induces apoptosis and counteracts substance P-related mitogenesis in human melanoma cell lines. Cancers 2:611–623
Rameshwar P, Gascón P (1995) Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: potential autoregulatory role for these cytokines in SP receptor expression and induction. Blood 86:482–490
Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112:231–238
Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792
Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: Implications for bone marrow metastasis. Proc Natl Acad Sci USA 97:1388–1393
Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 83:731–742
Esteban F, González-Moles MA, Castro D, Martín-Jaén MDM, Redondo M, Ruiz-Avila I, Muñoz M (2009) Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 54:258–260
Muñoz M, Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV (2008) Immunolocalization of the neurokinin-1 receptor: a new target in the treatment of the human primary retinoblastoma. In: Bospene EB (ed) Focus on eye neoplasma research progress. Nova Science, New York, pp 157–178
Muñoz M, Rosso M, Robles-Frías MJ, Salinas-Martín MV, Coveñas R (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90:1259–1269
Payan DG, McGillis JP, Organist ML (1986) Binding characteristics and affinity labeling of protein constituents of the human IM-9 lymphoblast receptor for substance P. J Biol Chem 261:14321–14329
Nowicki M, Miskowiak B, Ostalska-Nowicka D (2003) Detection of substance P and its mRNA in human blast cells in childhood lymphoblastic leukaemia using immunocytochemistry and in situ hybridisation. Folia Histochem Cytobiol 41:33–36
Harrison T, Owens AP, Willians BJ, Swain CJ, Baker R, Hutson PH, Sadowski S, Cascieri MA (1995) Piperidine-ether based hNK1 antagonists 2: investigation of the effect of N-substitution. Bioorg Med Chem Lett 5:209–212
Muñoz M, Pérez A, Coveñas R, Rosso M, Castro E (2004) Antitumoural action of L-733, 060 on neuroblastoma and glioma cell lines. Arch Ital Biol 142:105–112
Muñoz M, Pérez A, Rosso M, Zamarriego C, Rosso R (2004) Antitumoural action of NK1 receptor antagonist L-733, 060 on human melanoma cell lines. Melanoma Res 14:183–188
Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2007) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonists, L-732, 138. Invest Ophthalmol Vis Sci 48:2775–2781
Muñoz M, Rosso M, Coveñas R (2007) NK-1 receptor antagonists as new anti-tumoural agents: action on human neuroblastoma cell lines. In: Fernandes JA (ed) Focus on neuroblastoma research. Nova Science, New York, pp 31–56
Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-knowles E, Halle JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlsson EJ, Hargreaves RJ, Rupniak NM (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640–1645
Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, MacIntyre DE, Hargreaves RJ (2000) The novel NK-1 receptor antagonist MK-0869 (L-754, 030) and its water soluble phosphoryl prodrug, L-758, 298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39:652–663
Muñoz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28:187–193
Bigioni M, Benzo A, Irrissuto C, Maggi CA, Goso C (2005) Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 16:1083–1089
Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Büchler MW (2000) Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88:12–20
Shrikhande SV, Friess H, di Mola FF, Tempia-Caliera A, Conejo Garcia JR, Zhu Z, Zimmermann A, Büchler MW (2001) NK-1 receptor gene expression is related to pain in chronic pancreatitis. Pain 91:209–217
Moneo V, Serelde BG, Leal JFM, Blanco-Aparicio C, Díaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A (2007) Levels of p27kip1 determine Aplidin sensitivity. Mol Cancer Ther 6:1310–1316
Reeve JG, Bleehen NM (1994) [D-Arg1-D-Phe5, D-Trp7, 9, Leu11] Substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophys Res Commun 199:1313–1319
Esteban F, Muñoz M, González-Moles MA, Rosso M (2006) A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 25:137–145
Akazawa T, Kwatra KG, Goldsmith LE, RichardsonMD CEA, Sampson JH, Kwatra MM (2009) A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor- mediated apoptosis in glioblastomas. J Neurochem 109:1079–1086
Aguayo A, Giles F, Albitar M (2003) Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 44:213–222
Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F (2009) Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism. J Biol Chem 284:9280–9289
Fackler OT, Grosse R (2008) Cell motility through plasma membrane blebbing. J Cell Biol 181:879–884
Nowicki M, Miskowiak B (2003) Substance P - a potent risk factor in childhood lymphoblastic leukaemia. Leukemia 17:1096–1099
Palma C, Bigioni M, Irrissuto C (2000) Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82:480–487
Acknowledgements
This work was supported by the Consejería de Innovacion, Ciencia y Empresa of the Junta de Andalucía (CTS-2247, Spain). The technical assistance of Dr. Marisa Rosso is gratefully acknowledged. The authors thank N. Skinner for stylistic revision of the English text and Manuel Sánchez for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muñoz, M., González-Ortega, A. & Coveñas, R. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Invest New Drugs 30, 529–540 (2012). https://doi.org/10.1007/s10637-010-9594-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9594-0